Systemic lupus erythematosus (SLE)
.png "Diane Kamen, MD, MS photo")
Diane Kamen, MD, MS
Medical University of South Carolina
Charleston, SC, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Marta Mosca, MD, PhD
University of Pisa
Pisa, Pisa, Italy
Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
It is evident that for patients with moderate to severe lupus, single therapies are not adequate solutions. This session will provide case-based strategies for the use of newly approved medications, including biologic therapies, in combination with conventional medications for the treatment of lupus.
Using a case-based format, published data will be reviewed and guidance given for using emerging agents along with the standard therapies for patients with difficult to treat lupus nephritis and extra-renal lupus manifestations. Options to consider prospective strategies, combining biologic therapies will also be presented.
Speaker: David Isenberg, MD, FRCP – University College London
Speaker: Maria Dall'Era, MD – UCSF
